The 2022 Annual report of Promore Pharma AB is now available on the Company’s website.
STOCKHOLM, SWEDEN / ACCESSWIRE / May 9, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, 9 May, 2023 - The 2022 Annual report of Promore Pharma AB (publ) is now available on the Company’s website.
The annual report is available in PDF format on the Company’s website at:
https://www.promorepharma.com/en/section/investors/financial-reports/
Printed copies of the annual report can be ordered from Promore Pharma AB, Fogdevreten 2, SE-171 65 Solna, or by e-mail: shareholders@promorepharma.com
About Promore Pharma
Promore Pharma is a biopharmaceutical company that develops pharmaceutical product candidates for bioactive wound care. Today, the company has two drug candidates in late clinical development stages, that are based on endogenous peptides, and thus have a strong safety profile. These two products are intended for treatment of chronic wounds, and prevention of scarring on the skin and other tissues. The company is listed on the Nasdaq First North Growth Market.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Link to the report on our site
The full interim report is available at https://www.promorepharma.com/en/section/investors/financial-reports/
Attachments
Promore Pharma Annual Report 2022
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/753664/Promore-Pharmas-Annual-Report-2022
